Petersen Maya L, LeDell Erin, Schwab Joshua, Sarovar Varada, Gross Robert, Reynolds Nancy, Haberer Jessica E, Goggin Kathy, Golin Carol, Arnsten Julia, Rosen Marc I, Remien Robert H, Etoori David, Wilson Ira B, Simoni Jane M, Erlen Judith A, van der Laan Mark J, Liu Honghu, Bangsberg David R
*Division of Biostatistics, School of Public Health, University of California, Berkeley, Berkeley, CA; †Departments of Medicine (Infectious Disease) and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; ‡School of Nursing, Yale University, New Haven, CT; §Massachusetts General Hospital, Center for Global Health, Harvard Medical School, Boston, MA; ‖Health Services and Outcomes Research, Children's Mercy Hospitals and Clinics, University of Missouri-Kansas City Schools of Medicine and Pharmacy, Kansas City, MO; ¶Departments of Health Behavior and Medicine, School of Medicine and Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC; #Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY; **Department of Psychiatry, School of Medicine, Yale University, New Haven, CT; ††HIV Center for Clinical and Behavioral Studies, NY State Psychiatric Institute and Department of Psychiatry, Columbia University, New York, NY; ‡‡Department of Health Services, Policy & Practice, Brown University School of Public Health, Providence, RI; §§Department of Psychology, University of Washington, Seattle, WA; ‖‖Department of Health and Community Systems, University of Pittsburgh, School of Nursing, Pittsburgh, PA; ¶¶School of Dentistry, University of California, Los Angeles, Los Angeles, CA; and ##Massachusetts General Hospital, Center for Global Health, Department of Global Health and Population, Harvard School of Public Health, Boston, MA.
J Acquir Immune Defic Syndr. 2015 May 1;69(1):109-18. doi: 10.1097/QAI.0000000000000548.
Regular HIV RNA testing for all HIV-positive patients on antiretroviral therapy (ART) is expensive and has low yield since most tests are undetectable. Selective testing of those at higher risk of failure may improve efficiency. We investigated whether a novel analysis of adherence data could correctly classify virological failure and potentially inform a selective testing strategy.
Multisite prospective cohort consortium.
We evaluated longitudinal data on 1478 adult patients treated with ART and monitored using the Medication Event Monitoring System (MEMS) in 16 US cohorts contributing to the MACH14 consortium. Because the relationship between adherence and virological failure is complex and heterogeneous, we applied a machine-learning algorithm (Super Learner) to build a model for classifying failure and evaluated its performance using cross-validation.
Application of the Super Learner algorithm to MEMS data, combined with data on CD4 T-cell counts and ART regimen, significantly improved classification of virological failure over a single MEMS adherence measure. Area under the receiver operating characteristic curve, evaluated on data not used in model fitting, was 0.78 (95% confidence interval: 0.75 to 0.80) and 0.79 (95% confidence interval: 0.76 to 0.81) for failure defined as single HIV RNA level >1000 copies per milliliter or >400 copies per milliliter, respectively. Our results suggest that 25%-31% of viral load tests could be avoided while maintaining sensitivity for failure detection at or above 95%, for a cost savings of $16-$29 per person-month.
Our findings provide initial proof of concept for the potential use of electronic medication adherence data to reduce costs through behavior-driven HIV RNA testing.
对所有接受抗逆转录病毒治疗(ART)的HIV阳性患者进行常规HIV RNA检测成本高昂且收益较低,因为大多数检测结果为未检测到病毒。对失败风险较高的患者进行选择性检测可能会提高效率。我们调查了一种新的依从性数据分析方法是否能够正确分类病毒学失败情况,并可能为选择性检测策略提供依据。
多中心前瞻性队列联合研究。
我们评估了1478例接受ART治疗的成年患者的纵向数据,这些患者在美国16个参与MACH14联合研究的队列中使用药物事件监测系统(MEMS)进行监测。由于依从性与病毒学失败之间的关系复杂且具有异质性,我们应用机器学习算法(超级学习器)构建一个用于分类失败的模型,并使用交叉验证评估其性能。
将超级学习器算法应用于MEMS数据,并结合CD4 T细胞计数和ART方案数据,与单一的MEMS依从性指标相比,显著改善了病毒学失败的分类。在模型拟合未使用的数据上评估的受试者操作特征曲线下面积,对于定义为单一HIV RNA水平>1000拷贝/毫升或>400拷贝/毫升的失败情况,分别为0.78(95%置信区间:0.75至0.80)和0.79(95%置信区间:0.76至0.81)。我们的结果表明,在保持对失败检测的敏感性在95%或以上的同时,可以避免25%-31%的病毒载量检测,每人每月可节省16-29美元。
我们的研究结果为通过行为驱动的HIV RNA检测利用电子药物依从性数据降低成本的潜在用途提供了初步概念验证。